Medline Inc. - Class A common stock (MDLN)
41.11
+1.67 (4.23%)
NASDAQ· Last Trade: Jul 17th, 1:24 AM EDT
Detailed Quote
| Previous Close | 39.44 |
|---|---|
| Open | 39.64 |
| Bid | 40.30 |
| Ask | 41.10 |
| Day's Range | 39.42 - 41.30 |
| 52 Week Range | 32.81 - 50.88 |
| Volume | 6,298,683 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 8,219,225 |
Chart
News & Press Releases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 16, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 15, 2026
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 7, 2026
NORTHFIELD, Ill., July 01, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report second quarter 2026 financial results on Wednesday, August 5, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results.
By Medline Inc. · Via GlobeNewswire · July 1, 2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 30, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 30, 2026
NEW YORK, NY - June 30, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 30, 2026
NEW YORK, NY - June 29, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 29, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 29, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 27, 2026
NEW YORK, NY - June 27, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 27, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 26, 2026
NEW YORK, NY - June 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 25, 2026
NEW YORK, NY - June 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 25, 2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 23, 2026
NEW YORK, NY - June 20, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 19, 2026
NEW YORK, NY - June 19, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 19, 2026
NEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via NewMediaWire · June 18, 2026
NEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 17, 2026
NEW YORK, NY - June 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 17, 2026
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 16, 2026